Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $180

Moomoo NewsMar 25 01:31 ET

J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $200

Moomoo NewsMar 19 02:32 ET

Ascendis Pharma Price Target Raised to $200.00/Share From $168.00 by JP Morgan

Dow JonesMar 18 08:38 ET

Ascendis Pharma Is Maintained at Overweight by JP Morgan

Dow JonesMar 18 08:38 ET

Ascendis Pharma Analyst Ratings

BenzingaMar 18 08:28 ET

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $180

Moomoo NewsMar 18 02:33 ET

Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $181

Moomoo NewsMar 18 02:33 ET

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $180

Moomoo NewsMar 10 08:31 ET

Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $289

Moomoo NewsMar 6 07:33 ET

TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $162

Moomoo NewsMar 5 08:31 ET

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $180

Moomoo NewsMar 3 08:31 ET

Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $200

Moomoo NewsFeb 25 14:31 ET

Ascendis Pharma Analyst Ratings

BenzingaFeb 25 09:17 ET

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $180

Moomoo NewsFeb 24 08:31 ET

A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $180 to $289

Moomoo NewsFeb 19 08:00 ET

Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group

Dow JonesFeb 18 10:39 ET

Ascendis Pharma Analyst Ratings

BenzingaFeb 18 10:29 ET

Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $220

Moomoo NewsFeb 14 08:35 ET

A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $168 to $225

Moomoo NewsFeb 14 08:01 ET

Ascendis Pharma Is Maintained at Overweight by JP Morgan

Dow JonesFeb 13 11:07 ET